Literature DB >> 31987015

Increased Access to and Use of Endovascular Therapy Following Implementation of a 2-Tiered Regional Stroke System.

Nichole Bosson1,2,3, Marianne Gausche-Hill1,2,3, Jeffrey L Saver3,4, Nerses Sanossian5, Richard Tadeo2, Christine Clare2, Lorrie Perez2, Michelle Williams2, Sara Rasnake2, Phuong-Lan Nguyen2.   

Abstract

Background and Purpose- We quantified population access to endovascular-capable centers, timing, and rates of thrombectomy in Los Angeles County before and after implementing 2-tiered routing in a regional stroke system of care. Methods- In 2018, the Los Angeles County Emergency Medical Services Agency implemented transport of patients with suspected large vessel occlusions identified by Los Angeles Motor Scale ≥4 directly to designated endovascular-capable centers. We calculated population access to a designated endovascular-capable center within 30 minutes comparing 2016, before 2-tiered system planning began, to 2018 after implementation. We analyzed data from stroke centers in the region from 1 year before and after implementation to delineate changes in rates and speed of administration of tPA (tissue-type plasminogen activator) and thrombectomy and frequency of interfacility transfer. Results- With implementation of the 2-tier system, certified endovascular-capable hospitals increased from 4 to 19 centers, and within 30-minute access to endovascular care for the public in Los Angeles County, from 40% in 2016 to 93% in 2018. Comparing Emergency Medical Services-transported stroke patients in the first post-implementation year (N=3303) with those transported in the last pre-implementation year (N=3008), age, sex, and presenting deficit severity were similar. The frequency of thrombolytic therapy increased from 23.8% to 26.9% (odds ratio, 1.2 [95% CI, 1.05-1.3]; P=0.006), and median first medical contact by paramedic-to-needle time decreased by 3 minutes ([95% CI, 0-5] P=0.03). The frequency of thrombectomy increased from 6.8% to 15.1% (odds ratio, 2.4 [95% CI, 2.0-2.9]; P<0.0001), although first medical contact-to-puncture time did not change significantly, median decrease of 8 minutes ([95% CI, -4 to 20] P=0.2). The frequency of interfacility transfers declined from 3.2% to 1.0% (odds ratio, 0.3 [95% CI, 0.2-0.5]; P<0.0001). Conclusions- After implementation of 2-tiered stroke routing in the most populous US county, thrombectomy access increased to 93% of the population, and the frequency of thrombectomy more than doubled, whereas interfacility transfers declined.

Entities:  

Keywords:  Emergency Medical Services; neuron; odds ratio; reperfusion; thrombectomy

Year:  2020        PMID: 31987015     DOI: 10.1161/STROKEAHA.119.027756

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  3 in total

1.  Updated New York City Emergency Medical Services Acute Stroke Triage Protocol Reduces Interfacility Transfers and Time to Endovascular Thrombectomy for Emergent Large Vessel Occlusion Stroke Patients.

Authors:  Jacob R Morey; Brian D Kim; Michael Redlener; Xiangnan Zhang; Naoum Fares Marayati; Stavros Matsoukas; Emily Fiano; Laura K Stein; J Mocco; Johanna T Fifi
Journal:  J Stroke       Date:  2022-09-30       Impact factor: 8.632

2.  Machine Learning Automated Detection of Large Vessel Occlusion From Mobile Stroke Unit Computed Tomography Angiography.

Authors:  Luca Giancardo; Sunil A Sheth; Alexandra L Czap; Mersedeh Bahr-Hosseini; Noopur Singh; Jose-Miguel Yamal; May Nour; Stephanie Parker; Youngran Kim; Lucas Restrepo; Rania Abdelkhaleq; Sergio Salazar-Marioni; Kenny Phan; Ritvij Bowry; Suja S Rajan; James C Grotta; Jeffrey L Saver
Journal:  Stroke       Date:  2021-12-06       Impact factor: 10.170

3.  Access to Mechanical Thrombectomy for Ischemic Stroke in the United States.

Authors:  Hooman Kamel; Neal S Parikh; Abhinaba Chatterjee; Luke K Kim; Jeffrey L Saver; Lee H Schwamm; Kori S Zachrison; Raul G Nogueira; Opeolu Adeoye; Iván Díaz; Andrew M Ryan; Ankur Pandya; Babak B Navi
Journal:  Stroke       Date:  2021-05-13       Impact factor: 10.170

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.